Portfolio Management
Asset Lifecycle Value Management
Maximize and sustain your portfolio value.
To succeed in the fast-paced world of drug development, a comprehensive understanding of your target indications is crucial, including unmet medical needs, economic burden, as well as existing and upcoming competitive landscape.
How to rationalize strategic investments, optimize your portfolio, and sustain the value of your assets in the long run?
Our validated and transparent patient-level models and simulators accounting for disease and care diversity and evolution will help you rationalize early development plans, differentiate mature products from competition, and explore new indications and positioning through scenarii simulations.
Traditional approach : Fragmented access to real-world insights. High risks and limited ability to differentiate.
• Sparse aggregated data on target indications – limited visibility on future market evolutions.
• Empirical market share projections.
• Progressive decline versus upcoming competition.
• Inability to detect and seize repositioning or differentiation opportunities.
The new way : Integrated and prospective vision of target indications. Data-driven strategic decisions.
• Detailed understanding of unmet needs and strategic opportunities.
• Ability to simulate what-if scenarii based on existing and upcoming competition.
• Significantly more accurate market share projections.
• Ability to sustain asset portfolio through optimal positioning and differentiation.
The new way : Integrated and prospective vision of target indications. Data-driven strategic decisions.
• Detailed understanding of unmet needs and strategic opportunities.
• Ability to simulate what-if scenarii based on existing and upcoming competition.
• Significantly more accurate market share projections.
• Ability to sustain asset portfolio through optimal positioning and differentiation.
Our use-cases
- Project/Characterize high-value patients in RW
- De-risk outcome-based pricing
- Project market share scenarios
Identifying high-value PsA patients along disease progression to support portfolio value-based positioning
Psoriatic arthritis is a heterogenous rheumatic condition of which peripheral and axial manifestations can lead to irreversible structural damage and chronic disability. Characterizing high value patients (high costs / high response rates) across disease stages allows for differentiating and maximizing portfolio value, modeling structural damage and prescription scenarii to expand medical benefits. This project resulted in the identification of high-cost patients and robust predictors of radiographic progression. Systemic inflammation and higher body weight were identified as predictors of progression. Optimal positioning identified for multiple assets with higher cost but higher medical value and efficiency on fast progressors and/or high burden patients.
Identifying high-value PsA patients along disease progression to support portfolio value-based positioning
Psoriatic arthritis is a heterogenous rheumatic condition of which peripheral and axial manifestations can lead to irreversible structural damage and chronic disability. Characterizing high value patients (high costs / high response rates) across disease stages allows for differentiating and maximizing portfolio value, modeling structural damage and prescription scenarii to expand medical benefits. This project resulted in the identification of high-cost patients and robust predictors of radiographic progression. Systemic inflammation and higher body weight were identified as predictors of progression. Optimal positioning identified for multiple assets with higher cost but higher medical value and efficiency on fast progressors and/or high burden patients.
Maintaining reimbursement conditions based on long-term real-world cardiovascular outcomes projection in France
Inhibitor of intestinal cholesterol absorption is indicated as an adjuvant to diet in patients with primary hypercholesterolemia or mixed dyslipidemia. To date, there were no morbidity and mortality studies.
Bridging model combining real-world data collection with long-term outcome modelling allowed to confirm predictions in RW which led to maintain prices in France. It had a positive impact on sales volumes and prices in multiple other countries.
Maintaining reimbursement conditions based on long-term real-world cardiovascular outcomes projection in France
Inhibitor of intestinal cholesterol absorption is indicated as an adjuvant to diet in patients with primary hypercholesterolemia or mixed dyslipidemia. To date, there were no morbidity and mortality studies.
Bridging model combining real-world data collection with long-term outcome modelling allowed to confirm predictions in RW which led to maintain prices in France. It had a positive impact on sales volumes and prices in multiple other countries.
Forecast sales and patients flows under various positioning scenarii in a highly dynamic market
Metastatic castrate-resistant prostate cancer is a competitive and dynamic indication with many competitors reaching the market concomitantly. Anticipation of optimal positioning and relative cost-effectiveness depends on how prescription patterns will adapt based on new drugs effects and indications. Such projections can be done with proper tools and data.
Forecast sales and patients flows under various positioning scenarii in a highly dynamic market
Metastatic castrate-resistant prostate cancer is a competitive and dynamic indication with many competitors reaching the market concomitantly. Anticipation of optimal positioning and relative cost-effectiveness depends on how prescription patterns will adapt based on new drugs effects and indications. Such projections can be done with proper tools and data.